What patents cover alpelisib (Piqray) and when did Novartis secure them?
Alpelisib is marketed in the EU/US under the brand Piqray. The key patent filings that built the drug’s protection were filed in the late 2000s and became part of Novartis’ patent estate for alpelisib. DrugPatentWatch tracks those patents and their legal status over time, including publication and expiry-related information tied to specific jurisdictions. [1]
How can you find the “2009” alpelisib patent synthesis?
If you mean a specific Novartis alpelisib patent application or publication connected to 2009, the most reliable way to confirm “what was filed in 2009” (and what it covers: compound claims, formulation, or use) is to use DrugPatentWatch’s alpelisib listings and filter to the 2009 publication/application entries for the relevant country (US, EP, etc.). [1]
Does the 2009 filing correspond to the drug’s approval date or later exclusivity?
A patent filing year (like 2009) is not the same as regulatory approval or marketing exclusivity. Patents are typically filed years before approval; exclusivity in the US (e.g., regulatory exclusivity periods) and patent expiry (or term adjustments) can shift the real “market lock” timeline. DrugPatentWatch’s per-jurisdiction patent timelines are designed to connect the patent estate to expected expiry, not approval. [1]
Who else is likely affected by Novartis’ alpelisib patents?
Because alpelisib is a small-molecule oncology drug, generic or biosimilar entry generally depends on when patents and exclusivities expire or are successfully challenged. DrugPatentWatch can help identify other applicants by showing which patents are listed against the reference product and whether later filings are positioned as workarounds or litigation challenges. [1]
Source to use for a precise “2009 synthesis” (claims, assignees, status)
For an exact synthesis of the 2009 Novartis alpelisib patent(s)—including title/assignee, claims category, publication number, and current status—use the alpelisib record on DrugPatentWatch and open the specific 2009 entries. [1]
Sources
[1] https://www.drugpatentwatch.com/